Control of lipid metabolism by adipocyte FGFR1-mediated adipohepatic communication during hepatic stress

Nutrition and Metabolism

Volumn 9, Issue , 2012, Pages

  Yang, Chaofeng ^a   Wang, Cong ^a,d   Ye, Min ^a   Jin, Chengliu ^a,b   He, Weimin ^a,c   Wang, Fen ^a   McKeehan, Wallace L ^a   Luo, Yongde ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b GEORGIA STATE UNIVERSITY   (United States)

^c TEXAS SOUTHERN UNIVERSITY   (United States)

^d WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adipose tissue; FGF; FGFR; Fibroblast growth factor; Fibroblast growth factor receptor; Hepatic steatosis; Hepatic stress; Lipid metabolism; Starvation

Indexed keywords

BETAKLOTHO; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR 1; KLOTHO PROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FATTY LIVER; FIBROBLAST GROWTH FACTOR RECEPTOR 1 GENE; GENE; GENE EXPRESSION; LIPID METABOLISM; LIPOLYSIS; LIVER; MOUSE; NONHUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

MUS;

EID: 84867898251     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-9-94     Document Type: Article

References (39)

1. Fibroblast growth factor 21 corrects obesity in mice. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, Moller DE, Kharitonenkov A, Endocrinology 2008 149 6018 6027 10.1210/en.2008-0816 18687777
2. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA, Endocrinology 2004 145 2594 2603 10.1210/en.2003-1671 14976145 (Pubitemid 38686202)
3. FGF-21 as a novel metabolic regulator. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB, J Clin Invest 2005 115 1627 1635 10.1172/JCI23606 15902306 (Pubitemid 40814671)
4. The Klotho gene family as a regulator of endocrine fibroblast growth factors. Kurosu H, Kuro OM, Mol Cell Endocrinol 2009 299 72 78 10.1016/j.mce.2008.10.052 19063940
5. Pronounced variation in bile acid synthesis in humans is related to gender, hypertriglyceridaemia and circulating levels of fibroblast growth factor 19. Galman C, Angelin B, Rudling M, J Intern Med 2011 270 580 588 10.1111/j.1365-2796.2011.02466.x 22003820
6. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA, Cell Metab 2005 2 217 225 10.1016/j.cmet.2005.09.001 16213224
7. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. Lundasen T, Galman C, Angelin B, Rudling M, J Intern Med 2006 260 530 536 10.1111/j.1365-2796.2006.01731.x 17116003 (Pubitemid 44772372)
8. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis. Dasarathy S, Yang Y, McCullough AJ, Marczewski S, Bennett C, Kalhan SC, Eur J Gastroenterol Hepatol 2011 23 382 388 10.1097/MEG.0b013e328345c8c7 21448070
9. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver. Huang X, Yang C, Luo Y, Jin C, Wang F, McKeehan WL, Diabetes 2007 56 2501 2510 10.2337/db07-0648 17664243 (Pubitemid 47523257)
10. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W, J Hepatol 2010 53 934 940 10.1016/j.jhep.2010.05.018 20675007
11. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, Ozdogan O, Imeryuz N, Kalayci C, Avsar E, Eur J Clin Invest 2010 40 887 892 10.1111/j.1365-2362.2010.02338.x 20624171
12. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML, Maratos-Flier E, Gastroenterology 2010 139 456 463 10.1053/j.gastro.2010.04.054 20451522
13. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom I, Dahlin M, Amark P, Angelin B, Rudling M, Cell Metab 2008 8 169 174 10.1016/j.cmet.2008.06.014 18680716
14. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, Li Y, Goetz R, Mohammadi M, Esser V, Elmquist JK, Gerard RD, Burgess SC, Hammer RE, Mangelsdorf DJ, Kliewer SA, Cell Metab 2007 5 415 425 10.1016/j.cmet.2007.05.003 17550777 (Pubitemid 46825496)
15. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. Ito S, Fujimori T, Furuya A, Satoh J, Nabeshima Y, J Clin Invest 2005 115 2202 2208 10.1172/JCI23076 16075061 (Pubitemid 41134162)
16. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. Yu C, Wang F, Kan M, Jin C, Jones RB, Weinstein M, Deng CX, McKeehan WL, J Biol Chem 2000 275 15482 15489 10.1074/jbc.275.20.15482 10809780 (Pubitemid 30337280)
17. Metabolic regulator {beta}klotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. Luo Y, Yang C, Lu W, Xie R, Jin C, Huang P, Wang F, McKeehan WL, J Biol Chem 2010 285 30069 30078 10.1074/jbc.M110.148288 20657013
18. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. Yang C, Jin C, Li X, Wang F, McKeehan WL, Luo Y, PLoS One 2012 7 33870 10.1371/journal.pone.0033870 22442730
19. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Fon Tacer K, Bookout AL, Ding X, Kurosu H, John GB, Wang L, Goetz R, Mohammadi M, Kuro-o M, Mangelsdorf DJ, Kliewer SA, Mol Endocrinol 2010 24 2050 2064 10.1210/me.2010-0142 20667984
20. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, Mohammadi M, Rosenblatt KP, Kliewer SA, Kuro-o M, J Biol Chem 2007 282 26687 26695 10.1074/jbc.M704165200 17623664 (Pubitemid 47501965)
21. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E, Endocrinology 2009 150 4931 4940 10.1210/en.2009-0532 19819944
22. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, Inoue K, Fushiki T, Itoh N, Endocrinology 2009 150 4625 4633 10.1210/en.2009-0119 19589869
23. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R, Mohammadi M, Finck BN, Mangelsdorf DJ, Kliewer SA, Burgess SC, Proc Natl Acad Sci USA 2009 106 10853 10858 10.1073/pnas.0904187106 19541642
24. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Veniant MM, Diabetes 2009 58 250 259 10.2337/db08-0392 18840786
25. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. He W, Barak Y, Hevener A, Olson P, Liao D, Le J, Nelson M, Ong E, Olefsky JM, Evans RM, Proc Natl Acad Sci USA 2003 100 15712 15717 10.1073/pnas.2536828100 14660788 (Pubitemid 38021055)
26. FGFR1 is independently required in both developing mid- and hindbrain for sustained response to isthmic signals. Trokovic R, Trokovic N, Hernesniemi S, Pirvola U, Vogt Weisenhorn DM, Rossant J, McMahon AP, Wurst W, Partanen J, EMBO J 2003 22 1811 1823 10.1093/emboj/cdg169 12682014 (Pubitemid 36460138)
27. FGF signaling regulates mesenchymal differentiation and skeletal patterning along the limb bud proximodistal axis. Yu K, Ornitz DM, Development 2008 135 483 491 10.1242/dev.013268 18094024
28. Metabolism of isolated fat cells. I. Effects of hormones on glucose metabolism and lipolysis. Rodbell M, J Biol Chem 1964 239 375 380 14169133
29. A fat-specific enhancer is the primary determinant of gene expression for adipocyte P2 in vivo. Ross SR, Graves RA, Greenstein A, Platt KA, Shyu HL, Mellovitz B, Spiegelman BM, Proc Natl Acad Sci USA 1990 87 9590 9594 10.1073/pnas.87.24.9590 2263614 (Pubitemid 120016489)
30. GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice. Kammoun HL, Chabanon H, Hainault I, Luquet S, Magnan C, Koike T, Ferre P, Foufelle F, J Clin Invest 2009 119 1201 1215 10.1172/JCI37007 19363290
31. Role of Fgf receptor 2c in adipocyte hypertrophy in mesenteric white adipose tissue. Konishi M, Nakamura H, Miwa H, Chambon P, Ornitz DM, Itoh N, Mol Cell Endocrinol 2008 287 13 19 10.1016/j.mce.2008.02.010 18396371
32. Fundamentals of FGF19 & FGF21 action In Vitro and In Vivo. Adams AC, Coskun T, Irizarry Rovira AR, Schneider MA, Raches DW, Micanovic R, Bina HA, Dunbar JD, Kharitonenkov A, PLoS One 2012 7 38438 10.1371/journal.pone.0038438 22675463
33. Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. Chen W, Hoo RL, Konishi M, Itoh N, Lee PC, Ye HY, Lam KS, Xu A, J Biol Chem 2011 286 34559 34566 10.1074/jbc.M111.285965 21849508
34. Adiponectin: key player in the adipose tissue-liver crosstalk. Moschen AR, Wieser V, Tilg H, Curr Med Chem 2012 Epub ahead of print
35. Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients. Domingo P, Gallego-Escuredo JM, Domingo JC, Gutierrez Mdel M, Mateo MG, Fernandez I, Vidal F, Giralt M, Villarroya F, AIDS 2010 24 2629 2637 10.1097/QAD.0b013e3283400088 20935553
36. Serum FGF21 levels are increased in newly diagnosed type 2 diabetes with nonalcoholic fatty liver disease and associated with hsCRP levels independently. Li X, Fan X, Ren F, Zhang Y, Shen C, Ren G, Sun J, Zhang N, Wang W, Ning G, Yang J, Diabetes Res Clin Pract 2011 93 10 16 10.1016/j.diabres.2011.02.034 21596453
37. FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Ryden M, FEBS Lett 2008 582 1725 1730 10.1016/j.febslet.2008. 04.038 18460341
38. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. Veniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, Busby J, Vonderfecht S, Xu J, Lloyd DJ, PLoS One 2012 7 40164 10.1371/journal.pone. 0040164 22792234
39. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, Phamluong K, Feng B, Li L, Marsters S, Kates L, van Bruggen N, Leabman M, Wong A, West D, Stern H, Luis E, Kim HS, Yansura D, Peterson AS, Filvaroff E, Wu Y, Sonoda J, Sci Transl Med 2011 3 113 126